Supachaya Sriphoosanaphan MD, PhD

Gastroenterologist, Hepatologist and Asst. Professor at @ChulaHospital and @BumrungradH. PhD in Hepatology at @UCL (ผศ.ดร.นพ.ศุภพัชญ ศรีภูษณาพรรณ)

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

Delighted to have been awarded my PhD from @UCL after 3.5 unforgettable years of learning, challenges and growth.

Deepest thanks to my family, Prof. Rajiv Jalan, colleagues and everyone who supported me throughout this journey. 🎓

[Faculty of Medicine, Chulalongkorn U. @prmdcu]

ผศ.(พิเศษ) นพ.ศุภพัชญ ศรีภูษณาพรรณ ภาควิชาอาย���รศาสตร์ ได้รับแต่งตั้งให้ดำรงตำแหน่ง Board Committee จากสมาคม International Society for Hepatic Encephalopathy & Nitrogen Metabolism (ISHEN)

#MDCU #แพทย์จุฬาฯ #เกียรติภูมิแพทย์จุฬาฯ

[Frontline Gastro @FrontGastro_BMJ]

🚨 Introducing a brand new Frontline Gastroenterology Global Taskforce Member! 🌍🧠✨

Dr. Supachaya Sriphoosanaphan is a PhD candidate at University College London (UCL), London, UK, and a Transplant Hepatologist at Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand. His research focuses on improving outcomes in liver transplantation, liver failure, cirrhosis, and hepatocellular carcinoma.
X: @DrSupachaya
Facebook: Holmes Supachaya

#FGTaskforce #AIinGI #GlobalHealth #MedicalInnovation #Gastroenterology #FGJournal #DigitalHealth

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

Delighted to take part in #ISHEN2025

Grateful for the opportunity to present our data, and truly honoured that one of the posters was recognised with the Best Poster Award by @ISHENliver

Heartfelt thanks to Prof @RajivJalan1 and all my colleagues for making this possible.

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

@mapibafe @EASLnews @ReibergerThomas @RajivJalan1 Congratulations Mapi 🎉

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

A heartfelt thank you to Prof. @RajivJalan1 and the UCL Liver Failure Group for their unwavering support.

It was a joy meeting so many passionate and brilliant minds at #EASLCongress. Thank you for the inspiring conversations and shared curiosity. #EASL2025 @EASLnews

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

Apply here!

https://t.co/w1s7qiNiEj

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

🌏 Explore the Land of Smiles with a PhD visit to Chulalongkorn University in Thailand! 🇹🇭

📢 @ucl – @ChulalongkornU Turing Fund invites you to embark on a transformative academic journey.

Don't miss out on this chance!

📆 Deadline: 2 November
👇Apply now: link below

[JHEP Reports @JHEP_Reports]

🆕New review

➡️#Ammonia lowering may be a novel therapeutic strategy to control the symptoms and prevent the progression of #NAFLD

🔓#OpenAccess at👉https://t.co/zNNbhpK6A0

@AarhusUni
@RajivJalan1
#LiverTwitter

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

👍🏻 Exceptional recap!

[Elliot Tapper @ebtapper]

Statin timeline in #cirrhosis

1️⃣born to ⬇️portal pressure
2️⃣dined on ⬆️survival as secondary endpoint in trial to ⬇️variceal bleeding, ie AFTER decompensation
3️⃣thrived on obs studies confounded by immortal time & selection bias
🆘no benefit after decomp in RCT
#LiverTwitter

[NEJM @NEJM]

Late breaking at #EASLCongress: In this phase 2b, placebo-controlled trial involving patients with nonalcoholic steatohepatitis, pegozafermin, a long-acting glycopegylated FGF21 analogue, reduced fibrosis at 24 weeks. Full results by @drloomba et al.: https://t.co/mfRRrV2yX2

[Journal of Hepatology @JHepatology]

📢NEW

@EASLnews Clinical Practice Guidelines on acute-on-chronic liver failure

Available here:
https://t.co/GCNg1AIX9X

[EASL Education @EASLedu]

@EASLnews @AleksanderKrag @ThomasBerg24 @aelsharkawy75 @MajaThiele @jturnesv @AASLDtweets @alehlatam @Solda_Society @APASLnews @ebtapper @wong_yujun @Apichatka @rabataller @EASLEUAffairs @GlobalLiver @EuropeLiver @PBCRobert @marurinella @AASLDPresident Steatotic Liver Disease, the result of several years of disussion.

#LiverTwitter #EASLCongress #EASLStudio

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

@wonglaihung @Apichatka @EASLnews @EASLedu It was great meeting you in person today Prof Wong. 😊

[Laura Turco @Laura_Turco83]

✅️ Rivaroxaban improves PH complications-free survival!

▶️ A study that will change clinical practice!
Congratulations to the authors! 👏
@DraAngelaPuente @jcgarciapagan

[Rohit Loomba @DrLoomba]

Plenary talk #1 - MAESTRO-NASH Phase 3 histology data on resmetirom versus placebo by Stephen Harrison ⁦@Pinnacle_TX⁩ ⁦⁦@MadrigalPharma⁩ ⁦@EASLnews⁩ ⁦@AASLDtweets⁩ ⁦@AlkhouriNaim⁩ ⁦@NoureddinMD⁩ ⁦@NAFLDresearch⁩ ⁦@UCSD_GI⁩

[Jasmohan Bajaj @JasmohanBajaj]

Come join us for TOP-38 abstract studying #virome in #hepaticencephalopathy cross-sectionally & longitudinally. Selected for poster tour Friday! @ChulalongkornU @VCU_Liver @VAResearch @GeorgeMasonU

[Journal of Hepatology @JHepatology]

🆕Article in press❕

Development and validation of the AMMON-OHE model to predict risk of overt #hepaticencephalopathy occurrence in outpatients with #cirrhosis

Read it here👉https://t.co/AWBHTSEy66

@RajivJalan1
#LiverTwitter

[Supachaya Sriphoosanaphan MD, PhD @DrSupachaya]

@PeakNatapatMD @JeffHealthEH Congratulations kub

[UCL News @uclnews]

A liver #dialysis device, invented by researchers from @DoM_UCL and @UCLEnterprise spinout @YaqritLtd, has been proven safe and effective in treating severe #liver failure. The DIALIVE device could be approved for clinical use within three years @uclmedsci
https://t.co/pnI6eu1dpS